Monkeypox
MONDO:0002594An infection that is caused by an Orthopoxvirus, which is transmitted by primates or rodents, and which is characterized by a prodromal syndrome of fever, chills, headache, myalgia, and lymphedema; initial symptoms are followed by a generalized papular rash that typically progresses from vesiculation through crusting over the course of two weeks.
Also known as: Monkeypox virus infection, infections, Monkeypox virus
43 clinical trials for this condition and its sub-types, 40 tagged with Monkeypox itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New RNA mpox vaccine shows promise in early trial
Vaccine CompletedThis early-stage trial tested an RNA-based vaccine called BNT166a against mpox (monkeypox) in 96 healthy volunteers. The goal was to check safety and see if the vaccine triggers an immune response. Researchers looked for side effects like pain, fever, and fatigue, and monitored s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Sep 17, 2026 00:00 UTC
-
New vaccine trial aims to shield frontline workers from deadly mpox
Vaccine CompletedThis study tested the JYNNEOS smallpox vaccine in 1,600 healthcare workers in the Democratic Republic of the Congo who are at high risk of catching mpox. The goal was to see if the vaccine can prevent mpox infection and is safe to use. Participants received the vaccine and were m…
Phase 3 • Sponsor: Centers for Disease Control and Prevention • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
Could a smaller dose of monkeypox vaccine work just as well?
Vaccine CompletedThis study tested whether giving a smaller dose of the MVA-BN (JYNNEOS) monkeypox vaccine under the skin works as well as the standard full dose given into the muscle. About 229 healthy adults aged 18 to 50 received either one-fifth or one-tenth of the standard dose under the ski…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 12:08 UTC
-
Mpox vaccine shows promise for teens in new study
Vaccine CompletedThis study tested the JYNNEOS mpox vaccine in 450 healthy teens and adults to see if it works as well in adolescents aged 12-17 as it does in adults. Participants received two shots under the skin. The main goal was to compare immune responses and check for side effects. Results …
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 12:01 UTC
-
Monkeypox vaccine safety under the microscope in congo study
Vaccine CompletedThis completed study monitored the safety of the MVA-BN (Jynneos) vaccine in 500 adults at high risk for monkeypox in the Democratic Republic of the Congo. Participants received two doses of the vaccine and were followed for up to 28 days after their last dose. The main goal was …
Phase 4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 09:05 UTC
-
Monkeypox drug trial: can tecovirimat speed up healing?
Disease control CompletedThis study tested whether the drug tecovirimat is safe and effective for treating monkeypox (mpox). About 600 adults and children with confirmed mpox and active skin lesions took either tecovirimat or a placebo for 14 days, along with standard care. The main goal was to see how q…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Mpox drug TPOXX put to the test in 328-Patient trial
Disease control CompletedThis completed trial tested the antiviral drug tecovirimat (TPOXX) in 328 adults and children with mpox. Participants received either tecovirimat or a placebo to see if the drug speeds up healing of skin lesions. The study also tracked safety and natural disease progression durin…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 14:10 UTC
-
New rapid mpox tests could speed up diagnosis in remote areas
Diagnosis CompletedThis study will check how well three new rapid tests detect mpox virus compared to a standard lab test. Researchers will use about 80 stored skin swab samples from Uganda. The goal is to see if these quick, portable tests are accurate enough for use in places without full labs.
Sponsor: Foundation for Innovative New Diagnostics, Switzerland • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Can we better understand mpox in young people?
Knowledge-focused CompletedThis study gathers information from routine medical care on infants, children, and adolescents under 18 with confirmed mpox infection. Researchers aim to collect standardized data on symptoms, treatments, and outcomes to better understand how the disease affects young people. The…
Sponsor: PENTA Foundation • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Mpox secrets revealed: new study tracks virus clearance and transmission
Knowledge-focused CompletedThis completed study looked at 550 people with mpox to see how long the virus stays in the body and how it spreads to close contacts. Researchers measured viral levels in skin lesions, throat swabs, and blood over time. The goal is to provide better guidance on when it's safe to …
Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Mpox's hidden toll on eyes revealed in new study
Knowledge-focused CompletedThis study looked at 320 people with mpox to check for eye complications. Researchers performed standard eye exams to see what eye problems might occur. The goal was to better understand how often and in what ways mpox affects the eyes.
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC